LDS/Medical Tests/Phosphorylated Tau 181 (pTau-181), Plasma

Phosphorylated Tau 181 (pTau-181), Plasma

Tau proteins, encoded by the Microtubule-associated protein tau (MAPT) gene, are primarily localized within neuronal axons. They play a critical role in assembling, stabilizing, and regulating the spatial organization and dynamic properties of microtubules. Normally, tau proteins support axonal transport and maintain neuronal integrity.

In Alzheimer's disease (AD), pathological hyperphosphorylation of tau proteins occurs, leading to the formation of neurofibrillary tangles (NFTs), a hallmark neuropathological feature of AD. Hyperphosphorylated tau proteins aggregate into insoluble filaments, disrupting axonal transport, impairing neuronal function, and contributing to neuronal death and neurodegeneration.

Phosphorylation can occur at various amino acid residues including Thr181, Thr199, Ser202, Thr205, Thr217, Thr231, Ser235, and Ser396. Among these, phosphorylation at threonine 181 (pTau-181) has emerged as a highly reliable biomarker, strongly correlating with tau PET imaging in patients with suspected Alzheimer's disease. Elevated plasma pTau-181 concentrations correlate significantly with clinical severity, pathological progression, and dementia risk in AD patients. Furthermore, increased levels of pTau-181 are also detected in preclinical and prodromal stages, underscoring its utility for early diagnosis and disease monitoring.

  • Early diagnosis and monitoring of Alzheimer’s disease
  • Differentiation of Alzheimer’s disease from other cognitive disorders
  • Assessment of disease progression and therapeutic response in Alzheimer’s patients
  • Risk stratification and early detection in preclinical and prodromal Alzheimer's stages

Elevated plasma pTau-181 levels:

  • Highly suggestive of Alzheimer's disease or significant neurodegeneration associated with AD pathology.

    Normal plasma pTau-181 levels:

  • Decreased likelihood of Alzheimer's pathology; other causes of dementia should be considered.

0 to 55 years: 0.00 - 0.95 pg/mL

>55 years: 0.00 – 0.97 pg/mL

Electrochemiluminescence Immunoassay (ECLIA).

Plasma (EDTA).

Test results can be affected following consumption of high dose biotin within 72 hours prior sample collection.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 14 days
Amyloid Beta 42/40 Protein Ratio (Aβ42/40), Apolipoprotein E (APOE) genotyping, Vitamin B12 and Folate levels, Thyroid Stimulating Hormone (TSH), Calcium (Ca), Neuropsychological assessments and cognitive screening tests (e.g., MMSE, MoCA).
2 to 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login